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Background. Hepatitis C virus (HCV) nondetectability in the liver may predict a sustained viral response (SVR) in patients with
an end of treatment response. HCV RNA can be detected in liver tissue by in situ hybridization (ISH). Aim. To determine if
HCV nondetectability in liver allografts by ISH can predict SVR in patients who cleared virus serologically on treatment. Methods.
Twenty ﬁve patients with undetectable serum HCV on Interferon/Ribavirin therapy for HCV recurrence post liver transplant (LT)
were studied. All had biopsies at 4 months post LT (baseline) and follow up with HCV ISH analysis performed. Results.1 0w e r e
ISH positive (group 1); 15 were ISH negative (group 2). Groups 1 and 2 had similar patient, donor, and viral characteristics at LT,
as well as treatment duration at the time of the ISH assayed liver biopsy (13 ±16 versus 10±4m o n t h sP = .24). However, group 1
had longer total treatment duration (24 ± 10 versus 14 ± 5m o n t h s ,P = .001). Eight (80%) group 1 and 9 (60%) group 2 patients
achieved SVR. Mean grade and stage (modiﬁed Ishak score) were similar at 4 months, however, group 1 had higher grade (3 ±1.7
versus 1.6 ±1.3, P = .039) and stage (1.4 ±1.4v e r s u s0 .5 ±0.6, P = .084) on the ISH assayed biopsy, after similar post LT intervals
(23 ± 10 versus 24 ± 12 months, P = .91). Conclusion. Allograft HCV ISH nondetectability does not predict SVR in treatment
responsive HCV recurrence, but is associated with less severe histologic disease.
Copyright © 2009 M. Ghabril et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Hepatitis C virus (HCV) is the most common indication for
liver transplantation (LT) in the US with almost universal
recurrence following LT. The need for antiviral therapy is
common with up to 30% of patients progressing to cirrhosis
by 5 years [1]. Though the indication for antiviral therapy is
based on histologic ﬁndings, the primary goal of treatment
goal is serologically deﬁned by a sustained viral response
(SVR).
The absence of HCV RNA in liver tissue at the end of
treatment has been associated with SVR in HCV patients
with chronic liver disease treated with interferon-based
antiviral therapy [2]. A recently reported series in HCV LT
patients suggested that the presence or absence of allograft
HCV RNA following treatment predicted a relapse or SVR in
patients with a loss of viremia at the end of treatment. All 7
patients with a negative hepatic HCV RT-PCR at the end of
treatment had an SVR while 3 patients with HCV RT-PCR
present had relapse [3].
However, SVR status has not uniformly resulted in
histologic stabilization or ﬁbrosis regression. It has been
observed in a previous report that twenty percent of post
LT HCV patients experienced ﬁbrosis progression 3–5 years
following SVR [4, 5], while ﬁbrosis regression has been
described in treated patients without SVR [6]. Additionally,2 Journal of Transplantation
hepatic HCV RNA persistence has been described in patients
with SVR [7]. The correlation of hepatic allograft HCV RNA
detectability post LT with serum virologic endpoints and
histologic outcomes remains uncertain.
HCV RNA can be detected in liver tissue by polymerase
chain reaction (PCR), immunohistochemical, and in situ
hybridization (ISH) assays. HCV ISH utilizes digoxigenin
labeled riboprobes with sense (genomic) and antisense
(replicative intermediate) transcripts corresponding to the
5  noncoding region of the virus. It can be performed
on paraﬃn-embedded sections, with positive and negative
controls, and yields a qualitative result. It has been shown
to correlate well with tissue HCV RNA detection by PCR [8].
The primary aim of this study was to determine if
HCV nondetectability in liver allografts by ISH can predict
SVR in patients who cleared virus serologically on antiviral
treatment. A secondary aim was to determine the correlation
of allograft HCV-ISH status with histologic disease in this
patient subset.
2. Patientsand Methods
We retrospectively reviewed the records of HCV patients
undergoing LT at our center between February 1998 and
December 2005. The HCV ISH assay became available at
our institution in January 2003. It was performed in selected
patients with undetectable serum HCV by PCR while receiv-
ing antiviral therapy. These patients were further analyzed.
Data was retrospectively collected through April 2007. The
study was approved by the study centers Institutional Review
Board.
The ISH assay was performed as previously described
[8]. Patients were grouped by HCV ISH status (positive
or negative), and compared for (1) patient and donor
characteristics. (2) Antiviral therapy and virologic outcomes
of early viral response (EVR), end of treatment response
(ETR) and SVR. SVR was deﬁned as undetectable HCV RNA
in serum by qualitative assay ≥6 months after completion
of antiviral therapy. (3) Histologic ﬁndings of grade and
stage at baseline 4 months post LT (protocol biopsy) and at
the ISH assayed biopsy. Grading and staging of all biopsies
were performed using the modiﬁed Ishak score by a single
pathologist (MK) who was blinded to the ISH result, serum
viral status, and clinical ﬁndings [9].
All LT procedures were performed using piggy back
technique. Initial immunosuppression included a 3 drug
regimen of tacrolimus, mycophenolate mofetil and pred-
nisone, and tacrolimus monotherapy after 4 months post LT.
Protocol liver biopsies were performed at 7 days, 4 months,
and annually post LT, and as clinically indicated. Antiviral
therapy using Interferon (interferon alfa 2b prior to 2002
and peginterferon alfa 2a since 2002) and ribavirin was
initiated for signiﬁcant HCV recurrence. HCV recurrence
wasdeﬁnedasliverenzymeelevation ≥2×theupperlimitsof
normal, detectable serum HCV RNA, and histologic features
consistentwithhepatitisCwithBattsLudwigactivityscoreof
≥2 and/or progressive ﬁbrosis. Minimum planned duration
of therapy was 48 weeks for genotypes 1 and 4, and 24 weeks
for genotypes 2 and 3. Growth factors were used as clinically
indicated. Prior to 2005 serum HCV detectability was
determined by the Roche COBAS Amplicor HCV Monitor
2.0 assay (Roche Diagnostics, Indianapolis, IN) with a lower
limit of detection of 50IU/mL. Since 2005 serum HCV
was assayed with the COBAS TaqMan HCV Test (TaqMan
HCV; Roche Molecular SystemsInc., Branchburg, N.J.) with
a dynamic range of 10IU/mL to 50,000,000IU/mL.
3.StatisticalAnalysis
Patient groups were compared using the Mann-Whitney and
chi-square tests. SPSS 14.0 (SPSS Inc., Chicago, IL) was used
for the analysis. All P values were 2 tailed, and P<. 05 was
considered statistically signiﬁcant. All values are shown as
mean ± 1 SD, or percentage unless otherwise speciﬁed.
4. Results
LT for HCV were performed in 460 patients between 1998
and 2005 at our center and 231 (50%) underwent antiviral
treatment. Of the treated patients 73 (31.6%) had an on
treatment response, 44 had an SVR, 16 relapsed and 13
remained on treatment. HCV ISH assays of liver biopsies
were performed prospectively in 26/73 (36%) of the patients
with undetectable serum HCV by PCR while on treatment
between July 2004 and June 2006. Ten patients were ISH
positive(group1),15wereISHnegative(group2),and1was
excluded due to indeterminate ISH results. Serum HCV was
not detectable at the time of ISH assayed liver biopsies based
on the highly sensitive COBAS Taqman serum HCV RNA
assay in 22 (88%) of the 25 patients since 2005, and based
on the COBAS Amplicor HCV Monitor assay in 3 (12%)
patients before 2005.
Groups 1 and 2 were similar for patient, donor, and
viral characteristics, with the exception of a trend toward
more female patients in group 1 (Table 1). Antiviral therapy
timing, duration at the time of the ISH assayed biopsy,
treatment tolerance, and virologic outcomes were similar for
groups 1 and 2, with the exception of longer total treatment
duration in group 1 (Table 2). All patients received at least
the minimum planned duration of treatment per genotype.
Eight(80%)group1patientsachievedSVR,1(10%)relapsed
and 1 (10%) remained on therapy with undetectable serum
HCV at last follow up. Nine (60%) group 2 patients achieved
SVR, and 6 (40%) relapsed.
Antiviral treatment outcomes collated by patient group,
HCV genotype, duration of treatment at the time of ISH
assayed biopsy, total treatment duration, and timing of
virologic response are described for each case in Table 3.
After 12 weeks of therapy, HCV RNA was undetectable by
qualitative assay in 11 patients, and detectable in 8 (5 of
whom had EVR). A qualitative assay at 12 weeks was not
performed in 6 patients (5 of whom had EVR). Eight of
the 11 patients with undetectable serum HCV by 12 weeks
of therapy achieved SVR with treatment of at least the
minimum planned duration per genotype, while 2 relapsed,
and 1 remained on therapy for low levels of detectable HCVJournal of Transplantation 3
Table 1: Patient and donor characteristics, and antiviral therapy at the time the ISH biopsy in HCV ISH positive (group 1) and negative
(group 2) patients.
Variables Group 1 ISH positive N = 10 Group 2 ISH negative N = 15 P
Patient age at LT 49 ± 11 52 ± 11 .66
Female gender (patient) 40% 13% .13
Caucasian (patient) 90% 87% .69
Recipient body mass index 31 ± 72 9 ± 6. 5 1
MELD at LT 14 ± 51 8 ± 9. 4 2
Genotype 1 (unknown in 1 patient per group) 56% 86% .11
Donor age 47 ± 13 43 ± 14 .82
Female gender (donor) 40% 53% .51
Caucasian (Donor) 90% 67% .34
Cold ischemia time, hours 7 ± 27 ± 2. 7 4
Warm ischemia time, minutes 39 ± 93 4 ± 10 .28
Tacrolimus as primary immune suppressant 100% 83% .23
Steroid bolus treated ACR 30% 40% .61
LT to ISH biopsy interval, months 23 ± 10 24 ± 12 .91
Table 2: Antiviral therapy timing, duration, dose reductions, growth factor use, and virologic outcomes in treated group 1 and 2 patients.
Variable Group 1 ISH positive N = 10 Group 2 ISH negative N = 15 P
Pegylated IFN 100% 86% .23
Dose reduction 40% 33% .73
Growth factors used 80% 73% .70
LT-Treatment interval, months 6 ± 39 ± 7. 3 5
Treatment duration at ISH biopsy months 13 ± 61 0 ± 4. 2 4
Total treatment duration 24 ± 10 14 ± 5 .001
EVR 90% 86% .75
ETR 90%∗ 100% NA
SVR 80%∗ 60% .29
∗1 patient was still on treatment at last follow up.
(<10IU/mL) after >6 months of therapy. Seven of the 8
patients with detectable HCV at 12 weeks had undetectable
HCV by week 24. Four of these 7 patients received ≥24
weeks of additional therapy beyond their minimum planned
treatment duration per genotype, 3 achieved SVR, and
1 relapsed. The other 3 patients received <24 weeks of
additional therapy, and all 3 relapsed. One patient with
detectable serum HCV at week 24 became undetectable at
19 months, and achieved SVR after a total of 33 months of
therapy.
ALT, histologic grade, and stage were similar for the 2
groupsat4monthspostLT;however,atthetimeofthefollow
upISH biopsy they were higher in group 1patients (Table 4).
There were no deaths during the study period.
5. Discussion
The data from this study supports two primary ﬁndings.
First the absence of allograft HCV RNA by ISH did not
predict SVR in patients with an ETR. Second, there was
a correlation of liver allograft HCV RNA detectability by
ISH with increased disease activity and ﬁbrosis in the liver
allograft. This ﬁnding was independent of serologic viral
clearance.
Viral relapse in 7 of 14 patients with undetectable hepatic
HCV RNA by ISH on or at the end of completed treatment
was unexpected. A lack of sensitivity of the ISH assay is
one possibility. However, while there is no gold standard to
deﬁne HCV detectability in liver tissue, the ISH assay has
been shown to correlate well with tissue PCR techniques
and immunohistochemical assays [8]. Sampling variation
has been described in the grading and staging of liver
biopsies specimens in patients with chronic HCV [10].
Thus, this could also account for these ﬁndings as the ISH
assay was taken from only a single liver biopsy specimen.
Extrahepatic compartmentalization of HCV has been well
described and may theoretically explain these contradictory
ﬁndings[7,11].Extrahepaticsourcesmayprovidealternative
viral reservoirs and account for reinfection of the liver
following HCV RNA clearance from the liver and serum
while on treatment. The concept of extrahepatic reservoirs of
hepatotropic viruses has been well described with Hepatitis
B virus (HBV). HBV DNA has been found in serum and
lymphocytes many years following successful LT despite no
clinical evidence of HBV recurrence [12, 13].4 Journal of Transplantation
Table 3: Antiviral treatment duration and outcomes collated by patient group, HCV genotype, timing of ISH assayed biopsy and virologic
response.
Group,
genotype and
case number
ISH Status
Treatment
duration at ISH
assay (months)
Total treatment
duration
(months)
Viral load
response
HCV
undetectable
by 12 weeks
HCV
undetectable
by 24 weeks
Outcome
Group 1, genotype 2 or 3
1 + 12 12 EVR No Yes SVR
2 + 12 18 EVR NA Yes SVR
3 + 21 26 RVR Yes SVR
4 + 14 37 EVR Yes On therapy
Group 1, genotype 1 or unknown∗
5+ 4 1 8 E V R N o Y e s Relapse
6+ 5 1 9 E V R Y e s SVR
7∗ +9 1 8 E V R Y e s SVR
8 + 14 21 No EVR No Yes SVR
9 + 21 46 EVR NA Yes SVR
10 + 13 22 EVR Yes SVR
Group 2, genotype 2 or 3
11 − 71 1 R V R Y e s SVR
12 − 99 N o E V R N o Y e s Relapse
Group 2, genotype 1 or unknown∗
13 − 10 11 EVR NA Yes SVR
14 − 81 2 E V R N A Y e s Relapse
15 − 61 1 R V R Y e s SVR
16∗ − 81 2 E V R Y e s SVR
17 − 10 13 EVR Yes Relapse
18 − 14 14 EVR NA Yes SVR
19 − 11 12 EVR No Yes Relapse
20 − 20 33 No EVR No No SVR
21 − 31 2 E V R Y e s SVR
22 − 14 14 NA NA Yes SVR
23 − 71 2 E V R N o Y e s Relapse
24 − 13 17 EVR No Yes SVR
25 − 12 13 EVR Yes Relapse
NA: Not available; EVR: Early virologic response; RVR: Rapid virologic response; SVR: Sustained viral response.
∗The patients that did not have a known genotype.
Table 4: HCV viral loads, ALT, and modiﬁed Ishak score grade and stage for groups 1 and 2, at 4 months post LT and at the ISH biopsy.
Variables
Group 1
ISH positive
N = 10
Group 2
ISH negative
N = 15
P
4 month HCV titer x1,000,000IU/ml 1.2 ± 15 2.4 ± 4.4 .32
4m o n t hA L TI U 126 ± 92 168 ± 205 .68
4m o n t hg r a d e 3.6 ± 2.5 3.6 ± 2.7 .9
4m o n t hs t a g e 1 ± 1.2 0.5 ± 0.5 .39
4 month to ISH biopsy interval, months 19 ± 10 19 ± 12 .93
ISH biopsy ALT IU 69 ± 45 32 ± 27 .016
ISH biopsy grade 3 ± 1.7 1.6 ± 1.3 .039
ISH biopsy stage 1.4 ± 1.4 0.5 ± 0.6 .084Journal of Transplantation 5
Virologic relapse in those with an ETR and undetectable
hepatic HCV by ISH post LT in our series is at odds with the
ﬁndingofSVRinall7patientswithanETRandundetectable
hepatic HCV by PCR post LT in a prior study [3]. Both series
suﬀer from small sample size, but a diﬀerence in the assay
of hepatic HCV may account for the diﬀerence. ISH involves
in situ detection of viral RNA in hepatocytes, whereas PCR
analysis of homogenized liver tissue would include some
circulating lymphocytes harboring virus.
Our series comprised a select group including only
patients with loss of HCV serum RNA on treatment, thus
the higher than expected SVR rates were anticipated. There
was a statistically insigniﬁcant but numerically higher rate of
SVR in the ISH positive versus negative group, 80% versus
60%, respectively. However, the diﬀerences were most likely
due to the longer duration of antiviral treatment given and
a higher percentage of genotypes 2 or 3 in patients with
positive ISH (44% versus 14%). Longer duration of therapy
in group 1 patients was attributed to a treatment bias based
on the ﬁnding of positive HCV ISH, and likely reduced
relapse rates in the subset of patients with EVR, detectable
HCV at 12 weeks, and undetectable HCV at 24 weeks [14,
15]. Interestingly, the patient with detectable serum HCV
at 24 weeks cleared virus late into treatment and achieved
SVR.
Thesecondmajorﬁndingofthestudywasthecorrelation
of hepatic HCV RNA detectability by ISH with increased
histologic activity despite similar demographic factors in the
ISH positive and negative groups. The presence of HCV
RNA in native liver tissue has been associated with increased
histologicnecroinﬂammatoryactivityandﬁbrosisinpatients
with chronic liver disease secondary to HCV [16–19]. Post
LT, Neﬀ et al. noted that 6 of 7 patients with detectable
hepatic HCV by RT-PCR had grade 1-2 inﬂammation at
the end of treatment while in 3 of 4 patients with no
inﬂammationtheHCVRT-PCRintheliverwasundetectable
[3]. Our data may suggest an important role of hepatic
HCV RNA in eliciting or maintaining an immune response
regardless of a loss of HCV RNA in the serum. Allograft
histologic progression has been described in 20% of patients
threetoﬁveyearsfollowingserologicSVR[4,5],perhapsthis
could be accounted for by remnant hepatic HCV RNA.
I ns u m m a r y ,t h i si sar e t r o s p e c t i v es t u d ya n di sl i m i t e d
by sample size, but it suggests that hepatic HCV detectability
has limited value for predicting sustained virologic response
in post LT HCV patients achieving loss of HCV RNA on
current antiviral therapy. The correlation of hepatic HCV
RNAwithhistologic activityrepresentsapreliminaryﬁnding
which merits further investigation.
Abbreviations
HCV: Hepatitis C virus
LT: Liver transplantation
ISH: In situ hybridization
EVR: Early viral response
ETR: End of treatment response
SVR: Sustained viral response
PCR: Polymerase chain reaction.
References
[1] M. Berenguer, “Natural history of recurrent hepatitis C,” Liver
Transplantation, vol. 8, no. 10B, pp. S14–S18, 2002.
[2] M. Shindo, K. Arai, Y. Sokawa, and T. Okuno, “Hepatic
hepatitis C virus RNA as a predictor of a long-term response
to interferon-α therapy,” Annals of Internal Medicine, vol. 122,
no. 8, pp. 586–591, 1995.
[ 3 ]G .W .N e ﬀ,C .B .O ’ B r i e n ,R .C i r o c c o ,e ta l . ,“ P r e d i c t i o n
of sustained virological response in liver transplant recipi-
ents with recurrent hepatitis C virus following combination
pegylated interferon alfa-2b and ribavirin therapy using
tissue hepatitis C virus reverse transcriptase polymerase chain
reaction testing,” Liver Transplantation, vol. 10, no. 5, pp. 595–
598, 2004.
[4] M. F. Abdelmalek, R. J. Firﬁ, C. Soldevila-Pico, et al.,
“Sustained viral response to interferon and ribavirin in
liver transplant recipients with recurrent hepatitis C,” Liver
Transplantation, vol. 10, no. 2, pp. 199–207, 2004.
[5] T. Bizollon, P. Pradat, J.-Y. Mabrut, et al., “Beneﬁt of sustained
virological response to combination therapy on graft survival
of liver transplanted patients with recurrent chronic hepatitis
C,” American Journal of Transplantation,v o l .5 ,n o .8 ,p p .
1909–1913, 2005.
[6] T. Bizollon, P. Pradat, J.-Y. Mabrut, et al., “Histological
beneﬁt of retreatment by pegylated interferon alfa-2b and
ribavirin in patients with recurrent hepatitis C virus infection
posttransplantation,”AmericanJournalofTransplantation,vol.
7, no. 2, pp. 448–453, 2007.
[7] M. Radkowski, J. F. Gallegos-Orozco, J. Jablonska, et al.,
“PersistenceofhepatitisCvirusinpatientssuccessfullytreated
for chronic hepatitis C,” Hepatology, vol. 41, no. 1, pp. 106–
114, 2005.
[ 8 ]X .Q i a n ,R .B .G u e r r e r o ,T .B .P l u m m e r ,V .F .A l v e s ,a n dR .V .
Lloyd, “Detection of hepatitis C virus RNA in formalin-ﬁxed
paraﬃn-embedded sections with digoxigenin-labeled cRNA
probes,” Diagnostic Molecular Pathology, vol. 13, no. 1, pp. 9–
14, 2004.
[9] K. Ishak, A. Baptista, L. Bianchi, et al., “Histological grading
and staging of chronic hepatitis,” Journal of Hepatology, vol.
22, no. 6, pp. 696–699, 1995.
[10] A. Regev, M. Berho, L. J. Jeﬀers, et al., “Sampling error and
intraobserver variation in liver biopsy in patients with chronic
HCV infection,” American Journal of Gastroenterology, vol. 97,
no. 10, pp. 2614–2618, 2002.
[11] G. Di Liberto, A. Roque-Afonso, R. Kara, et al., “Clinical and
therapeutic implications of hepatitis C virus compartmental-
ization,” Gastroenterology, vol. 131, no. 1, pp. 76–84, 2006.
[12] S. Ciesek, F. A. Helfritz, U. Lehmann, et al., “Persistence
of occult hepatitis B after removal of the hepatitis B virus-
infected liver,” Journal of Infectious Diseases, vol. 197, no. 3, pp.
355–360, 2008.
[13] M. Hussain, C. Soldevila-Pico, S. Emre, V. Luketic, and A. S.
F. Lok, “Presence of intrahepatic (total and ccc) HBV DNA is
not predictive of HBV recurrence after liver transplantation,”
Liver Transplantation, vol. 13, no. 8, pp. 1137–1144, 2007.
[14] T. Berg, M. von Wagner, S. Nasser, et al., “Extended treatment
duration for hepatitis C virus type 1: comparing 48 versus 72
weeks of peginterferon-alfa-2a plus ribavirin,” Gastroenterol-
ogy, vol. 130, no. 4, pp. 1086–1097, 2006.
[15] A. Mangia, N. Minerva, D. Bacca, et al., “Individualized
treatment duration for hepatitis C genotype 1 patients: a
randomized controlled trial,” Hepatology, vol. 47, no. 1, pp.
43–50, 2008.6 Journal of Transplantation
[16] M. Chang, A. P. Marquardt, B. L. Wood, et al., “In situ
distribution of hepatitis C virus replicative-intermediate RNA
in hepatic tissue and its correlation with liver disease,” Journal
of Virology, vol. 74, no. 2, pp. 944–955, 2000.
[17] V. Dries, I. von Both, M. M¨ uller, et al., “Detection of hepatitis
C virus in paraﬃn-embedded liver biopsies of patients
negative for viral RNA in serum,” Hepatology, vol. 29, no. 1,
pp. 223–229, 1999.
[18] G. J. Nuovo, A. Holly, P. Wakely Jr., and W. Frankel, “Corre-
lation of histology, viral load, and in situ viral detection in
hepaticbiopsiesfrompatientswithlivertransplantssecondary
to hepatitis C infection,” Human Pathology,v o l .3 3 ,n o .3 ,p p .
277–284, 2002.
[19] S. Pal, M. C. Shuhart, L. Thomassen, et al., “Intrahepatic
hepatitis C virus replication correlates with chronic hepatitis
C disease severity in vivo,” Journal of Virology, vol. 80, no. 5,
pp. 2280–2290, 2006.